Tissue Regenix Group (TRX) Share Price, News & Analysis

Company Overview

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care. In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

Key Stats

• Today's Range: 44 to 46
• 50-Day Range: 44 to 60
• 52-Week Range: 44 to 75
• Volume: 137,630 shs
• Average Volume: 60,841 shs
• Market Capitalization: £40.39 million
• P/E Ratio: N/A
• Dividend Yield: 4.12%
• Price Target: N/A
• Consensus Rating: N/A

TRX Stock Analysis - Frequently Asked Questions

How have TRX shares performed this year?

Tissue Regenix Group's stock was trading at GBX 60 at the beginning of 2025. Since then, TRX stock has decreased by 25.3% and is now trading at GBX 44.80.
View the best growth stocks for 2025 here.

How were Tissue Regenix Group's earnings last quarter?

Tissue Regenix Group plc (LON:TRX) released its quarterly earnings data on Wednesday, September, 2nd. The company reported ($0.16) earnings per share for the quarter. Tissue Regenix Group had a negative trailing twelve-month return on equity of 2.87% and a negative net margin of 3.46%.

How do I buy shares of Tissue Regenix Group?

Shares of TRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Tissue Regenix Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tissue Regenix Group investors own include Lloyds Banking Group (LLOY), Argos Therapeutics (ARGSQ), FuelCell Energy (FCEL), TransEnterix (TRXDW), Swedbank AB (publ) (SWDBY), Trevena (TRVN) and Barrick Gold (ABX).

Company Calendar

• Last Earnings: 9/02/2020
• Today: 2/21/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Precious Metals
• Current Symbol: LON:TRX
• CUSIP: N/A
• CIK: N/A
• Web: www.tissueregenix.com
• Phone: +44-1904-567609
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 89.21
• P/E Growth: N/A
• Net Income: £-1,105,225.70
• Net Margins: -3.46%
• Pretax Margin: N/A
• Return on Equity: -2.87%
• Return on Assets: 0.50%

Debt

• Debt-to-Equity Ratio: 31.16
• Current Ratio: 4.03
• Quick Ratio: 2.36

Sales & Book Value

• Annual Sales: £31.98 million
• Price / Sales: 1.26
• Cash Flow: GBX 7.86 per share
• Price / Cash Flow: 5.70
• Book Value: GBX 41.58 per share
• Price / Book: 1.08

Miscellaneous

• Outstanding Shares: 90,155,317
• Free Float: N/A
• Market Cap: £40.39 million
• Optionable: Not Optionable
• Beta: 1.61